Crystal Pharmatech, a company located in SIP, opened its doors to a number of partners on July 23, showcasing to them its 15-year R&D outcomes and future blueprint as a leading technology-driven contract research organization (CRO) and contract development and manufacturing organization (CDMO) for drug development.
Established in 2010, the company provides integrated and specialized services for innovative drug discovery and development, including crystallization, formulation development and biological analysis.
So far, the company has provided services for more than 1,000 innovative drugs companies worldwide, offering solutions for the development of more than 2,000 new drug compounds, with a year-on-year increase of 70% in operating income last year.
Crystal Pharmatech established Crystal Bio Solutions after acquiring an American biological analysis laboratory early this year, marking a significant improvement of its capability of serving the whole process of innovative drug discovery and development.
The company plays a critical role in promoting coordinated development within the biomedical industry chain in SIP. Of its 55 clients in Suzhou, 30 are located in SIP, and an incubator has been set up in its office building that came into use late last year, with six businesses engaged in biomedicine and related sectors under incubation.
July 25, 2025
